Proteasome stress activates YAP/TAZ through the RAP2-MAP4Ks-LATS1/2 pathway and its therapeutic implications in solid
Xin Wang1, Yuan Gu1,2, Zhenxing Zhong1
1Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Summary
Proteasome inhibitors are limited in solid tumors due to Hippo pathway activation. Blocking yes-associated protein (YAP)/TAZ overcomes this resistance, offering a new combination therapy strategy for aggressive cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Proteasome inhibitors are effective in hematologic cancers but not solid tumors.
- Drug resistance in cancers is often linked to activation of yes-associated protein (YAP)/TAZ, key effectors of the Hippo pathway.
- The precise mechanisms underlying proteasome inhibitor resistance in solid tumors remain unclear.
Purpose of the Study:
- To investigate the role of proteasome stress in activating the Hippo pathway in solid tumor cells.
- To elucidate the signaling cascade linking proteasome inhibition to YAP/TAZ activation.
- To evaluate the therapeutic potential of combining proteasome inhibitors with YAP/TAZ inhibition in solid tumors.
Main Methods:
- Utilized proteasome inhibition in solid tumor cells to induce proteasome stress.
- Investigated the ubiquitination and inactivation of RAP2 upon proteasome inhibition.
- Analyzed the disruption of the RAP2-MAP4Ks-NF2-LATS1/2 signaling pathway.
- Assessed the impact of YAP/TAZ activation on cell survival and drug resistance.
- Evaluated the efficacy of combined proteasome and YAP/TAZ inhibition in diffuse-type gastric cancer models.
Main Results:
- Proteasome stress was identified as an upstream signal activating the Hippo pathway in solid tumor cells.
- Proteasome inhibition led to RAP2 ubiquitination and inactivation, disrupting the RAP2-MAP4Ks-NF2-LATS1/2 pathway.
- This disruption resulted in the activation of YAP/TAZ, promoting cell survival and resistance to proteasome inhibitors.
- Inhibition of YAP/TAZ restored cancer cell sensitivity to proteasome inhibitors.
- Combined inhibition of proteasome and YAP/TAZ effectively suppressed tumor growth in diffuse-type gastric cancer.
Conclusions:
- Proteasome stress is an upstream activator of the Hippo pathway in solid tumors.
- YAP/TAZ activation mediates resistance to proteasome inhibitors in solid tumors.
- Targeting YAP/TAZ in combination with proteasome inhibitors presents a promising therapeutic strategy for solid tumors, including diffuse-type gastric cancer.
More Related Videos
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:31Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
01:19Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
01:31The Intrinsic Apoptotic Pathway
8.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
01:07MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K